Intranasal Ketamine Versus Intravenous Ketorolac for Pain Control in the Renal Colic: A Randomized Clinical Trial Study

Ali Khavanin¹, Meisam Moezzi^{1,*}, Hassan Motamed¹, Samaneh Parozan¹ and Abdolreza Hosseini¹

¹Department of Emergency Medicine, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Department of Emergency Medicine, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: meisam.moezzi@yahoo.com

Received 2021 March 22; Revised 2021 April 20; Accepted 2021 May 03.

Abstract

Background: Renal colic is one of the most common complaints among patients referring to the emergency department (ED). Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are gold standards to refer patients.

Objectives: The aim of this study was to evaluate the effects of intranasal Ketamine on pain control versus Ketorolac.

Methods: In this randomized clinical trial (RCT), the patients were randomly assigned into two groups. Ketorolac 30 mg was given intravenously to all patients in the control group, the patients in intervention group received 1 mg/kg drops of Ketamine intranasally. Pain severity, vital signs, and adverse events (AEs) were recorded after 60 minutes post-dose.

Results: A total of 100 patients were enrolled in this study. The mean visual analog scale (VAS) score after the first 5 minutes was lower in the intranasal Ketamine group compared to control (5 ± 2.26 vs. 8.62 ± 0.49 , respectively; $P < 0.001$), which remained significant at the end of 60th minutes ($P < 0.001$). Moreover, additional analgesics administration was higher in intravenous Ketorolac than intranasal Ketamine (22 vs 0%), which was significantly different ($P = 0.001$). Patients' satisfaction was higher in the intranasal Ketamine group compared to control (3.56 ± 0.35 vs. 1.82 ± 0.98 , respectively; $P < 0.001$).

Conclusions: Intranasal Ketamine was beneficial in controlling renal colic-induced pain, which could be prescribed as a treatment instead of normal treatment. It can rapidly improve pain relief in the short term, has lower AEs, and increases the patients' satisfaction.

Keywords: Urinary Calculi, Renal Colic, Pain Management, Ketamine, Ketorolac

1. Background

Renal colic is a common complaint among patients referring to emergency departments (EDs) (1% of presentations to EDs) (1), and it is seen in 5 - 15% of subjects' lifetime (2). The movement of renal stone in the urinary tract is a common cause of severe groin pain. Both non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are gold standards for relieving pain with acute renal colic (3, 4). Although opioids are potent and cheap, but they have some adverse events (AEs) such as nausea, vomiting, constipation, respiration depression (in larger doses), drowsiness, and hypotension (5). Compare with NSAIDs, opioid has fewer complications such as drowsiness, vomiting, and nausea; but it was demonstrated they can develop AEs such as nephropathy and platelet dysfunction (6). Concerning various AEs of opioids and NSAIDs, discovering new drugs with adequate analgesic properties and fewer AEs is essential (7).

Ketamine is an arylcyclohexylamine that acts mainly

on glutamate binding sites, N-Methyl-D-Aspartate receptors (NMDA), and non-NMDA receptors cause psych sensory effects, amnesia analgesia, and neuroprotection (8). Ketamine is used as a procedure not requiring any musculoskeletal relaxation or in short surgeries. This drug can be prescribed for all groups of patients except in exceptional cases such as patients with severe hypertension, brain traumas, cardiovascular diseases, and heart attack (9, 10). Ketamine is administered intravenously and/or intramuscularly (11), but it can also be administered intranasally with few effects on the heart (12). As far as the researchers investigated, there is not sufficient clinical studies on the efficacy of intranasal Ketamine on renal colic.

2. Objectives

This study aimed to evaluate the clinical efficacy of intranasal Ketamine in renal colic and compare it with traditional treatment methods [intravenous NSAIDs (Ketorolac)].

3. Methods

3.1. Study Design

The current survey is a single-center, randomized phase III clinical trial to compare the effect of intranasal Ketamine versus intravenous Ketorolac for pain control in the renal colic patients in Imam Khomeini Hospital of Ahvaz, Iran from November 2019 to May 2020. The study protocol was approved by the Medical Ethics Committee of Jundishapur Ahvaz University (reference number: IR.AJUMS.U-97023) and it was performed as a phase III clinical trial (code: IRCT20180526039846N1).

3.2. Participants

Based on clinical and para-clinical findings [ultrasound and computed tomography (CT) scan], the patients were identified by emergency medicine specialists. All participants signed a written informed consent.

3.3. Inclusion Criteria

The inclusion criteria were: (1) patients referred to ED with acute renal pain (severity more than five based on a visual analog scale [VAS]) based on the radiological examinations and clinical history; (2) aged over 18 years; and (3) not received analgesic drugs for at least six hours.

3.4. Exclusion Criteria

Patients with a history of allergy to ketamine or ketorolac (toradol), aspirin or ibuprofen, contraindications to ketorolac or ketamine, unstable vital signs, fluctuations in alertness, underlying diseases such as liver cirrhosis (chronic alcoholism), recent gastrointestinal bleeding, and perforation in the last five days or renal failure, previous renal surgery, hypertension, history of any type of cardiac diseases, abdominal tenderness suspected of peritonitis, chronic respiratory diseases, nasal obstruction, brain tumors, acute head traumas, history of seizure, any type of metabolic diseases, history of peptic ulcer, glaucoma, history of drug addiction, history of psychological disorders, malignancy, pregnancy and lactation, unconfirmed stone-induced renal colic, and body temperature over 38°C were excluded.

3.5. Intervention

The control group received Ketorolac 30 mg/kg (in bolus form) and placebo intranasally. In the intervention group, Ketamine 1 mg/kg was prescribed intranasally and placebo intravenously. Patients with a VAS score ≥ 3 received 1 $\mu\text{g/kg}$ of IV fentanyl as rescue analgesia. In patients suffering from dehydration or sepsis, 10 mL/kg liquid therapy was used. During the treatment period, all patients were under the supervision of emergency medicine specialists. Also, patients with incomplete data were excluded.

3.6. Outcomes Assessment

The pain intensity was a 10-cm horizontal line. This line was written with 'pain with the most intensity' on the right with a score of 10 and 'no pain' on the left with a score of zero (13). The primary outcome was assessed for pain reduction before administration, 5, 15, 30, and 45 minutes after administration. For this evaluation, relief pain ≤ 30 based on VAS score was considered significant. After 30 minutes of the drug administration, no significant reduction in pain was observed ($\Delta\text{VAS} \geq 3$); the Fentanyl 1 $\mu\text{g/kg}$ with 5-minute interval time was prescribed until the intensity of pain was reduced. The secondary outcome was assessed according to the time of staying in an emergency room (between 1 - 2 hours), the value of financial of treatment, the need for lifesaving therapy (used for patients with VAS ≥ 5 after 60 minutes), side effects after 60 minutes, and measuring satisfaction based on 5-point Likert scale (0 = poor to 4 = excellent) 60 minutes after administration. Vital signs of the patients and AEs after treatment, such as dizziness, rash, headache, tachycardia, breath distress, blurred vision, and vomiting were recorded.

3.7. Statistical Analysis

To compare qualitative variables and determine the normal distribution of quantitative parameters, chi-square test and the Kolmogorov-Smirnov test were used, respectively. T-test and Mann-Whitney test were used for variables with normal and without distribution, respectively. To evaluate the differences between the groups in different periods, repeated measures ANOVA was used. A P-value < 0.05 was considered as significant. All data were analyzed by SPSS software (V24).

4. Results

In this study, a total of 100 patients were randomly divided into two groups (intranasal Ketamine and intravenous Ketorolac) (Figure 1). The patients' mean age was 34.39 ± 5.60 years, and 71 (71%) were male (Table 1). In patients who did not respond to treatment after 30 minutes, fentanyl 1 $\mu\text{g/kg}$ with 5-minute interval time was prescribed until the pain reduced; in this regard, no patients were excluded from the study.

Before the intervention, there was no significant difference between the two groups in terms of the studied variables, including VAS score and hemodynamic parameters ($P > 0.05$). The mean VAS score in the intranasal Ketamine and control groups after the first 5 minutes (5 ± 2.26 vs. 8.62 ± 0.49 , respectively; $P < 0.001$) and 60 minutes ($P < 0.001$) was lower in the intervention group as compared to the control. A substantial decreasing pattern in pain level

Figure 1. CONSORT-style diagram

was found in the two groups from the start to minutes 5 and 60 ($P < 0.001$) (Figure 2A). Furthermore, pulse rate did not differ between the two groups at any time ($P > 0.05$), and the repeated measures ANOVA test did not show differences between the two groups in different periods ($F = 0.985$, $P = 0.323$) (Figure 2B). The use of fentanyl to control AEs was more frequent in the control group (22 vs. 0%) ($P = 0.001$) (Table 1). The frequency of AEs was the same between the two groups ($P = 0.117$).

Our results showed that hospitalization duration in ED was remarkably lower in the intranasal Ketamine group (89.3 ± 10.35 min) as compared to the intravenous Ketorolac group (101.04 ± 15.25 min) ($P < 0.001$). No significant differences were seen in terms of blood pressure ($F = 0.006$, $P = 0.938$) and respiratory rate ($F = 0.002$, $P = 0.966$) between the two groups (Figure 2C and D). Finally, patients' satisfaction was significantly higher in intranasal Ketamine group compared to the control (3.56 ± 0.35 vs. 1.82 ± 0.98 , respectively; $P < 0.001$).

was found in the two groups from the start to minutes 5 and 60 ($P < 0.001$) (Figure 2A). Furthermore, pulse rate did not differ between the two groups at any time ($P > 0.05$), and the repeated measures ANOVA test did not show differences between the two groups in different periods ($F = 0.985$, $P = 0.323$) (Figure 2B). The use of fentanyl to control AEs was more frequent in the control group (22 vs. 0%) ($P = 0.001$) (Table 1). The frequency of AEs was the same between the two groups ($P = 0.117$).

5. Discussion

Pain management is vital in patients with renal stones, and most medications used for this purpose are intramuscular and intravenous or oral opioids and NSAIDs. Ketamine, as an opium alternative, is an analgesic drug in relieving acute pain with different administration methods such as intranasal (14). The bioavailability of intranasal

Table 1. Studied Variables in Different Periods among Control and Intervention Groups ^a

Variables	Intranasal Ketamine (n = 50)	Intravenous Ketorolac (n = 50)	P-Value
Age (y)	33.66 ± 7.61	34.84 ± 6.67	0.412
Sex (male)	35 (70)	36 (72)	0.826
Pain (VAS score)			
Before intervention	9.62 ± 0.53	9.5 ± 0.54	0.239
After 5 min	5 ± 0.4	8.62 ± 0.49	< 0.001
After 15 min	1.6 ± 0.49	6.8 ± 0.53	< 0.001
After 30 min	0.6 ± 0.57	3.68 ± 0.47	< 0.001
After 45 min	0.6 ± 0.57	2.06 ± 0.72	< 0.001
After 60 min	0.5 ± 0.5	1.96 ± 0.69	< 0.001
AEs	0	4 (8)	0.117
Fentanyl administration	0	11 (22)	0.001
Hospitalization duration (min)	89.3 ± 10.35	101.04 ± 15.25	< 0.001
Patients' satisfaction	3.56 ± 0.35	1.82 ± 0.98	< 0.001

Abbreviations: VAS, visual analog scale; AEs, adverse events.

^a Values are expressed as mean ± SD and No. (%). **Figure 2.** The differences between 2 groups during different time for A, VAS score; B, pulse rate; C, systolic blood pressure; D, respiratory rates.

Ketamine is 45%, the peak volume of plasma was seen in less than 30 minutes, and the terminal half-life is around 2 hours (15).

According to our results, renal colic-induced pain was controlled better in cases treated with intranasal ketamine compared to intravenous ketorolac in the first 5 minutes after drug administration. There were no significant differ-

ences in rate of complications and hemodynamic changes between the intervention and control groups. On the other hand, our findings showed that the additional analgesia administration was significantly lower in the intranasal ketamine group. Finally, intranasal ketamine increased patient satisfaction. This is inconsistent with the recent findings that intranasal ketamine can be helpful when accom-

panied by other medications (16). One explanation for this difference can be the administration of different drugs in control group. Pouraghaei et al. (2020) compared the effect of intranasal ketamine versus intravenous morphine, and showed that intranasal ketamine is more effective and it has lower AEs (17). This is in line with the results of Farnia et al., which indicated that intranasal ketamine could help alleviate pain compared to intravenous morphine (18).

Carr et al. showed that blood level of ketamine in intranasal administration can reach a detectable level after two minutes, with a median duration of nearly 30 minutes (19). Moreover, other studies showed that the effect of intranasal ketamine in reducing pain would last for three hours (20). In our study, the pain was relieved 5 and 60 minutes post-administration, whereas in the study by Shrestha et al. the pain score decreased 15 minutes after administration (21).

Likewise, intranasal ketamine was observed by Yeaman et al. within 30 minutes, in which the pain severity was lowered by 2.4 units (22). Furthermore, Andolfatto et al. (23) showed that intranasal Ketamine can minimize the pain score depending on VAS score by at least 1.3 units after 30 minutes, which is inconsistent with the present survey. In contrast, no significant differences for reliving pain scores were observed in the same study (24).

After analyzing for AEs, our data demonstrated that dizziness and nausea were the most common AEs among patients, which is consistent with the studies by Shrestha et al. and Andolfatto et al. Additionally, their survey revealed intranasal ketamine could be useful in patients with acute injury (21, 23). The short follow-up period and a small sample size were the main limitations of the current investigation.

5.1. Conclusions

This findings of current study revealed the positive benefits of intranasal ketamine compared to standard treatment in managing pain due to renal colic. This substantial therapy can contribute to dramatically increasing short-term pain regulation with reduced AEs and enhanced patient satisfaction.

Acknowledgments

We acknowledge the Emergency Medicine Department of Imam Khomeini Hospital in Ahvaz, Iran for the kind help. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Footnotes

Authors' Contribution: M.M conceived the manuscript and revised it. A.K., H.M., and S.P. performed experimental analysis, wrote the manuscript, and prepared tables and figures.

Clinical	Trial	Registration	Code:
IRCT20180526039846N1			

Conflict of Interests: The authors declare no conflict of interest. All procedure performs in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or compared ethical strand.

Ethical Approval: The study protocol was approved by the Medical Ethics Committee of Jundishapur Ahvaz University (Reference Number: IR. AJUMS.U-97023) and it was performed as a phase III clinical trial (code: IRCT20180526039846N1).

Funding/Support: There is no funding for the current study.

Informed Consent: All participants signed a written informed consent.

References

- Hockberger RS. *Rosen's emergency medicine concepts and clinical practice*. Amsterdam, Netherlands: Elsevier Inc; 2018.
- Maleki Verki M, Porozan S, Motamed H, Fahimi MA, Aryan A. Comparison the analgesic effect of magnesium sulphate and Ketorolac in the treatment of renal colic patients: Double-blind clinical trial study. *Am J Emerg Med*. 2019;37(6):1033–6. doi: [10.1016/j.ajem.2018.08.040](#). [PubMed: [30172601](#)].
- Curry C, Kelly AM. Intravenous tenoxicam for the treatment of renal colic. *N Z Med J*. 1995;108(1001):229–30. [PubMed: [7603654](#)].
- Smally AJ. Analgesia in renal colic. *Ann Emerg Med*. 1997;29(2):296–9. doi: [10.1016/s0196-0644\(97\)70288-9](#).
- Godara S, Srivastava R, Vashist M, Godara R. Lornoxicam versus diclofenac sodium in acute renal colic: A prospective randomized trial. *Int J Basic Clin Pharmacol*. 2013;2(2):193. doi: [10.5455/2319-2003.ijbcp20130314](#).
- Ghosh R, Alajbegovic A, Gomes AV. NSAIDs and cardiovascular diseases: Role of reactive oxygen species. *Oxid Med Cell Longev*. 2015;2015:536962. doi: [10.1155/2015/536962](#). [PubMed: [26457127](#)]. [PubMed Central: [PMC4592725](#)].
- Masoumi K, Forouzan A, Asgari Darian A, Feli M, Barzegari H, Khavanin A. Comparison of clinical efficacy of intravenous acetaminophen with intravenous morphine in acute renal colic: A randomized, double-blind, controlled trial. *Emerg Med Int*. 2014;2014:571326. doi: [10.1155/2014/571326](#). [PubMed: [25197573](#)]. [PubMed Central: [PMC4147290](#)].
- Metry AA, Fahmy NG, Nakhla GM, Wahba RM, Ragaei MZ, Abdelmalek FA. Lornoxicam with low-dose ketamine versus pethidine to control pain of acute renal colic. *Pain Res Treat*. 2019;2019:3976027. doi: [10.1155/2019/3976027](#). [PubMed: [31001434](#)]. [PubMed Central: [PMC6436326](#)].

9. Laskowski K, Stirling A, McKay WP, Lim HJ. A systematic review of intravenous ketamine for postoperative analgesia. *Can J Anaesth*. 2011;**58**(10):911–23. doi: [10.1007/s12630-011-9560-0](https://doi.org/10.1007/s12630-011-9560-0). [PubMed: [21773855](https://pubmed.ncbi.nlm.nih.gov/21773855/)].
10. Khademi S, Ghaffarpasand F, Heiran HR, Yavari MJ, Motazedian S, Dehghankhalili M. Intravenous and peritonsillar infiltration of ketamine for postoperative pain after adenotonsillectomy: A randomized placebo-controlled clinical trial. *Med Princ Pract*. 2011;**20**(5):433–7. doi: [10.1159/000327657](https://doi.org/10.1159/000327657). [PubMed: [21757932](https://pubmed.ncbi.nlm.nih.gov/21757932/)].
11. Marx J, Hockberger R, Walls R. *Rosen's emergency medicine - concepts and clinical practice e-book*. Amsterdam, The Netherlands: Elsevier Health Sciences; 2013.
12. Weinbroum AA. Non-opioid IV adjuvants in the perioperative period: pharmacological and clinical aspects of ketamine and gabapentinoids. *Pharmacol Res*. 2012;**65**(4):411–29. doi: [10.1016/j.phrs.2012.01.002](https://doi.org/10.1016/j.phrs.2012.01.002). [PubMed: [22311381](https://pubmed.ncbi.nlm.nih.gov/22311381/)].
13. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and measure of intermittent and constant osteoarthritis pain (ICOAP). *Arthritis Care Res (Hoboken)*. 2011;**63 Suppl 11**:S240–52. doi: [10.1002/acr.20543](https://doi.org/10.1002/acr.20543). [PubMed: [22588748](https://pubmed.ncbi.nlm.nih.gov/22588748/)].
14. Singh V, Gillespie TW, Harvey RD. Intranasal ketamine and its potential role in cancer-related pain. *Pharmacotherapy*. 2018;**38**(3):390–401. doi: [10.1002/phar.2090](https://doi.org/10.1002/phar.2090). [PubMed: [29396996](https://pubmed.ncbi.nlm.nih.gov/29396996/)].
15. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. *Clin Pharmacokinet*. 2016;**55**(9):1059–77. doi: [10.1007/s40262-016-0383-6](https://doi.org/10.1007/s40262-016-0383-6). [PubMed: [27028535](https://pubmed.ncbi.nlm.nih.gov/27028535/)].
16. Mozafari J, Maleki Verki M, Motamed H, Sabouhi A, Tirandaz F. Comparing intranasal ketamine with intravenous fentanyl in reducing pain in patients with renal colic: A double-blind randomized clinical trial. *Am J Emerg Med*. 2020;**38**(3):549–53. doi: [10.1016/j.ajem.2019.05.049](https://doi.org/10.1016/j.ajem.2019.05.049). [PubMed: [31155169](https://pubmed.ncbi.nlm.nih.gov/31155169/)].
17. Pouraghaei M, Moharamzadeh P, Paknezhad SP, Rajabpour ZV, Soleimanpour H. Intranasal ketamine versus intravenous morphine for pain management in patients with renal colic: A double-blind, randomized, controlled trial. *World J Urol*. 2021;**39**(4):1263–7. doi: [10.1007/s00345-020-03319-4](https://doi.org/10.1007/s00345-020-03319-4). [PubMed: [32591901](https://pubmed.ncbi.nlm.nih.gov/32591901/)].
18. Farnia MR, Jalali A, Vahidi E, Momeni M, Seyedhosseini J, Saeedi M. Comparison of intranasal ketamine versus IV morphine in reducing pain in patients with renal colic. *Am J Emerg Med*. 2017;**35**(3):434–7. doi: [10.1016/j.ajem.2016.11.043](https://doi.org/10.1016/j.ajem.2016.11.043). [PubMed: [27931762](https://pubmed.ncbi.nlm.nih.gov/27931762/)].
19. Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: A randomized, double-blind, placebo-controlled, crossover study. *Pain*. 2004;**108**(1-2):17–27. doi: [10.1016/j.pain.2003.07.001](https://doi.org/10.1016/j.pain.2003.07.001). [PubMed: [15109503](https://pubmed.ncbi.nlm.nih.gov/15109503/)].
20. Hugu V, Lauchart M, Magerl W, Schelling G, Beyer A, Thieme D, et al. Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. *Eur J Pain*. 2010;**14**(4):387–94. doi: [10.1016/j.ejpain.2009.08.002](https://doi.org/10.1016/j.ejpain.2009.08.002). [PubMed: [19733106](https://pubmed.ncbi.nlm.nih.gov/19733106/)].
21. Shrestha R, Pant S, Shrestha A, Batajoo KH, Thapa R, Vaidya S. Intranasal ketamine for the treatment of patients with acute pain in the emergency department. *World J Emerg Med*. 2016;**7**(1):19–24. doi: [10.5847/wjem.j.1920-8642.2016.01.003](https://doi.org/10.5847/wjem.j.1920-8642.2016.01.003). [PubMed: [27006733](https://pubmed.ncbi.nlm.nih.gov/27006733/)]. [PubMed Central: [PMC4786493](https://pubmed.ncbi.nlm.nih.gov/PMC4786493/)].
22. Yeaman F, Meek R, Egerton-Warburton D, Rosengarten P, Graudins A. Sub-dissociative-dose intranasal ketamine for moderate to severe pain in adult emergency department patients. *Emerg Med Australas*. 2014;**26**(3):237–42. doi: [10.1111/1742-6723.12173](https://doi.org/10.1111/1742-6723.12173). [PubMed: [24712757](https://pubmed.ncbi.nlm.nih.gov/24712757/)].
23. Andolfatto G, Willman E, Joo D, Miller P, Wong WB, Koehn M, et al. Intranasal ketamine for analgesia in the emergency department: A prospective observational series. *Acad Emerg Med*. 2013;**20**(10):1050–4. doi: [10.1111/acem.12229](https://doi.org/10.1111/acem.12229). [PubMed: [24127709](https://pubmed.ncbi.nlm.nih.gov/24127709/)].
24. Elia N, Tramer MR. Ketamine and postoperative pain—a quantitative systematic review of randomised trials. *Pain*. 2005;**113**(1-2):61–70. doi: [10.1016/j.pain.2004.09.036](https://doi.org/10.1016/j.pain.2004.09.036). [PubMed: [15621365](https://pubmed.ncbi.nlm.nih.gov/15621365/)].